Alnylam and Regeneron Plan 50/50 Gene R&D Pact To Find NASH RNAi Drugs
Duo to equally share development costs and profits from any candidates emerging from their RNAi discovery pact.
You may also be interested in...
Already partnered with Regeneron in NASH, Alnylam unveils a new R&D collaboration in eye, CNS and liver indications, after Alnylam and Sanofi end the research phase of their relationship.
Along with last week's acquisition of three NASH candidates from Lilly by Terns, NASH remains a heavily crowded R&D space as the European Association for the Study of the Liver annual meeting approaches.
ApolloBio signs on to take Inovio's HPV immunotherapy into China and Senju and Fosun sign China partnerships – all part of a wave of Chinese companies looking to bring innovative new medicines to the Greater China markets. Meanwhile, GSK signs on with Indian CRO Syngene.